PPMI Completed & Ongoing Biologic Analyses
Principal InvestigatorOrganizationProject TitleData AvailabilityAnalyteMatrixIncluded Enrollment CohortsSubcategories includedVisit(s)Project IDNotes
 Collaboration powered by Smartsheet   |   Report Abuse
1Andrew Singleton, PhDNIAAPOE4 Genotyping​Currently available
APOE4 genotyping​
DNA from whole bloodHealthy Control
Parkinson Disease
SWEDD (legacy)
NABaseline104
2Clemens Scherzer, MDHarvardEvaluation of PD-linked Transcripts in PPMICurrently available
aSyn transcripts
RNA from whole bloodHealthy Control
Parkinson Disease
NABaseline105
3Andrew Singleton, PhDNIAImmunochip Genotyping on DNA Samples from PPMICurrently available
Immunochip genotyping​
DNA from whole bloodHealthy Control
Parkinson Disease
SWEDD (legacy)
NABaseline108
4Alice Chen-Plotkin, MD, MScUPennPlasma Apolipoprotein A1 Level as a Biomarker in Parkinson’s DiseaseCurrently available
ApoA1 & EGF​
PlasmaHealthy Control
Parkinson Disease
NABaseline, 6, 12 months112
5Maria Teresa Pellecchia, PhDUniversity of SalernoInsulin-like Growth Factor-1 as a Biomarker of Early Cognitive Impairment in PDCurrently available
IGF-1
SerumHealthy Control
Parkinson Disease
NABaseline113
6Judith Potashkin, PhDRosalind & Franklin UniversityWhole Blood RNA Biomarkers of PDCurrently available
mRNA transcripts
RNA from whole bloodHealthy Control
Parkinson Disease
NABaseline114
7Matthew Farrer, PhDUniversity of BCClinical, Imaging, & Plasma & CSF Correlates of aSyn Genomic VariabilityCurrently available
SNCA genotyping​
DNA from whole bloodHealthy Control
Parkinson Disease
NABaseline115
8Andrew Singleton, PhDNIAExome Sequencing of PPMI samplesCurrently available
Whole exome sequencing
DNA from whole bloodHealthy Control
Parkinson Disease
SWEDD (legacy)
NABaseline116
9Andrew Singleton, PhDNIAWhole Genome Sequencing & Analysis of PPMI Prodromal & Genetic Cohorts & Genetic Registry​Currently available
Whole genome sequencing
DNA from whole bloodHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaseline118
10Martin Rabey, MDBioShai Ltd.Validation of a Blood-based Gene Expression Assay for Early Diagnosis & Monitoring DiseaseCurrently available
mRNA transcripts
RNA from whole bloodHealthy Control
Parkinson Disease
SWEDD (legacy)
NABaseline, 12, 24, 36 months119
11Dena Hernandez, PhDNIA​DNA Methylation in PPMICurrently available
DNA methylation
DNA from whole bloodHealthy Control
Parkinson Disease
SWEDD (legacy)
NABaseline120
12Thomas Kremer, PhD; Kristen Taylor, PhDRocheCSF Neurotransmitter Metabolites as Promising Diagnostic & Disease Severity Biomarkers in Early-Stage PD Patients​Currently available
Catecholamines​
CSFHealthy Control
Parkinson Disease
NABaseline, 12, 24 months122
13Dwight German, PhDUT SouthwesternBlood biomarker for PDCurrently available
PD2 peptoid
SerumHealthy Control
Parkinson Disease
NABaseline123
14Andrew Singleton, PhDNIAGBA SequencingCurrently available
GBA sequencing
DNA from whole bloodHealthy Control
Parkinson Disease
SWEDD (legacy)
NABaseline126
15Satpal Virdee, PhD,University of Dundee​Profiling PINK1-Parkin Functionality in Patient Fibroblasts Using Chemical ProbesCurrently available
PINK1
FibroblastsHealthy Control
Parkinson Disease
NAn/a127
16Xinnan Wang, PhDStanford University​Miro, a Biomarker for Parkinson’s DiseaseCurrently available
Miro
Fibroblasts
iPSCs
Healthy Control
Parkinson Disease
Prodromal
Genetic subjectsn/a129
17Gavin Hudson, PhDNewcastle UniversityThe Role of Cell-Free Mitochondrial DNA in Neurodegenerative DiseaseCurrently available
Cell-free mitochondrial DNA
CSFHealthy Control
Parkinson Disease
NABaseline, 36 months130
18Nilima Prakash, PhDHamm-Lippstadt University of Applied Sciences​Altered Calcium Activity Patterns in Developing Dopaminergic Neurons from PD Patients as an Early Indicator of Disease Predisposition or ProgressionCurrently available
Calcium activity
Fibroblasts
iPSCs
Healthy Control
Parkinson Disease
NAn/a136
19Rachit Bakshi, PhDMGH/MIND​Urate & Nrf2 Pathway Effects on Mutant LRRK2 Toxicity in iPSC-Derived DA NeuronsCurrently available
Urate & Nrf2​
iPSCsHealthy Control
Parkinson Disease
Prodromal
LRRK2 subjectsn/a137
20Mark Cookson, PhD​NIALRRK2 Genetic Risk Variants in PDExpected Q3 2023
LRRK2 functional variants​
iPSCsHealthy Control
Parkinson Disease
Prodromal
Genetic subjectsn/a139
21Travis Dunckley, PhD; Paula Desplats, PhDArizona State University; UCSDComprehensive Methylation Profiling of the PPMI Cohort​Currently available
Methylation profiling​
DNA from whole bloodHealthy Control
Parkinson Disease
Prodromal
LRRK2 subjectsBaseline, 12, 24, 36 months140
22Nic Dzamko, PhDUniversity of Sydney​Inflammatory phenotypes in differentiated human LRRK2 & GBA mutation IPS cell linesCurrently available
Inflammation/​lysosomal function
iPSCsHealthy Control
Parkinson Disease
Prodromal
GBA & LRRK2 subjectsn/a141
23Danielle Graham, PhD; Brit Mollenhauer, MDBiogen; Paracelsus Elena KlinikInvestigation of Neurofilament Light Chain in Serum from the PPMI Cohorts as Progression Marker for PD​Currently available
Neurofilament Light (NFL)​
SerumHealthy Control
Parkinson Disease
Prodromal
Genetic subjectsPD & HC: Baseline, 6, 12, 24, 36, 60 months; Prodromal & genetic cohorts: Baseline, 6, 12, 24, 36 months144
24Kalpana Merchant, PhDTransTheraDo Urinary BMP Levels Change with Disease Progression in Idiopathic & Genetic PD?Currently available
BMP
UrineHealthy Control
Parkinson Disease
Prodromal
GBA & LRRK2 subjectsPD, HC, & GBA: Baseline only; LRRK2: Baseline, 12, 24 months145
25Dimitri Krainc, MDNorthwestern UniversityConvergence of LRRK2 & GBA1 in the Pathogenesis of Parkinson’s DiseaseExpected Q2 2023
GCase activity in dopaminergic neurons​
iPSCsHealthy Control
Parkinson Disease
LRRK2 subjectsn/a148
26Matt LaVoie, PhDBrigham & Women’s, Harvard​Role of LRRK2 in Gcase-mediated Alterations in Lysosome Functions & aSyn MetabolismExpected Q2 2023
LRRK2 at lysosomes
iPSCsParkinson DiseaseGBA subjectsn/a149
27Andy Singleton, PhDNIAThe Foundational Data InitiativeCurrently available; interactive portal currently under development, expected Q3 2021
Transcriptional activity, gene regulation, epigenetics​
iPSCsHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsn/a150Data portal under development
28Fiona Elwood, PhDNovartisIdentification of Proteins & Protein Networks in Human CSF That Differentiate Within PD Patients​Currently available
SomaLogic collaboration (with Merck & Novartis)​
CSFHealthy Control
Parkinson Disease
Prodromal
Genetic subjectsBaseline151
29Richard Batrla-Utermann, PhDRocheRoche NeuroTool KitCurrently available
Roche Elecsys NeuroTool Kit (aSyn, GFAP, IL-6, S100b, neurogranin, NFL, sTREM2, YKL40)​
CSFHealthy Control
Parkinson Disease
NABaseline, 6, 12, 24, 36, 48 months152
30Thomas Schwarz, PhDBoston Children’s Hospital​Mitochondrial Transport Defects as a Potential Biomarker in Patient-derived Cells10HC, 3 SNCA, 1 LRRK2, 2 PD lines available; Remaining expected Q1 2023​
Mitochondrial transport​
iPSCsHealthy Control
Parkinson Disease
Genetic subjectsn/a153
31Ellen Sidransky, MD​NIHDevelopment of Novel TRPML1 Activator for Treatment of PDExpected Q3 2023
Calcium channel agonists
iPSCsHealthy Control
Parkinson Disease
NAn/a154
32Claudio Soto, PhDAmprionMonitoring the Progression & Pre-clinical Diagnosis of PD by Detection of aSyn Oligomers in CSF Using the PMCA AssayCurrently available
aSyn seeding (PMCA)- Round Robin & Phase 2​
CSFHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsPhase 1: BL, 36, mo; Phase 2: PD, HC, SWEDD at BL, prodromals at all visits, SNCA at all visits, LRRK2/GBA PD at BL and NMC at BL & all visits for phenoconverted155Phase 1 (Baseline & 36 months) PD, CT, SWEDD currently available; remaining data expected EOY
33Aaron Day WilliamsFlagship 60​Investigation of Phenotypic Differences Between Familial PD, Idiopathic PD and Controls in Patient-derived iPSCsCurrently available
Phenotyping
iPSCsHealthy Control
Parkinson Disease
Prodromal
LRRK2 subjectsn/a156
34Marlene Jacobson, PhDUniversity of Dundee​Investigating the Effect of Small Molecules to Rescue Lysosomal & GBA-1 Deficiencies in GBA-PDCurrently available
Lysosomal rescue​
FibroblastsHealthy Control
Parkinson Disease
NAn/a158
35Les Shaw, PhDUPennPPMI CSF A-beta42, t-tau, and p-tau 181 Analysis 2019Currently available
Aβ, tau, & p-tau181 ​
CSFHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaseline, 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 months15975 Bridging study & 2,000+ remaining PPMI samples not yet analyzed from previous efforts
36Sulev Koks, MD, PhDMurdoch UniversityAssociation of Repetitive Elements with Parkinson's Disease Risk and Progression in the PPMI CohortCurrently available
Tandem repeats
DNAHealthy Control
Parkinson Disease
NABaseline160
37Maximiliano Gutierrez, PhDFrancis Crick Institute​The Role of LRRK2 Kinase Activity in Human Macrophage FunctionExpected Q2 2023
LRRK2 kinase activity
iPSCsParkinson DiseaseLRRK2 subjectsn/a161
38Liana Rosenthal, MDJohn HopkinsIs Poly ADP-ribose in the CSF a Biomarker for PD Diagnosis or Progression?​Currently available
Poly ADP-ribose​
CSFHealthy Control
Parkinson Disease
NABaseline, 6, 12, 18, 24, 36,48, 60 months165
39Claudio Soto, PhDUniversity of Texas​A Novel Model of Parkinson’s Disease in Lab-generated Mini-brainsExpected Q2 2023
Characterization of midbrain organoids​
iPSCsHealthy Control
Parkinson Disease
LRRK2 & SNCA subjectsn/a166
40Manoj Pandey, PhDCincinnati Children’s Hospital​Setting up the Translational Value of Complement 5a Induction of Brain Inflammation & Neuronal Loss in Human Patients w/ Parkinson’s DiseaseExpected Q2 2023
Neuroinflammation
iPSCsHealthy Control
Parkinson Disease
GBA subjectsn/a167
41Eleanor Coffey, PhDTurku Centre for Biotechnology​PD Signature Validation Project Related to "Improving Patient Diagnosis, Stratification & Disease Monitoring in PD"Expected Q3 2023
Protein handling
PBMCsHealthy Control
Parkinson Disease
Prodromal
Genetic subjects3 longitudinal timepoints170
42Cornelis Blauwendraat, PhDNIALong read DNA sequencing of the PPMI cohort​Expected Q3 2023
Long read DNA sequencing​
DNA from whole bloodHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaseline171
43Byron Caughey, PhDNIHaSyn Seeding Assay Round Robin- NIH​Currently available
aSyn seeding​ (RT-QuIC)- Round Robin
CSFHealthy Control
Parkinson Disease
SWEDD (legacy)
NABaseline, 36 months172
44Roland Heym, PhDAbbvieEvaluation of Seeding-competent aSyn in the CSF as a Biomarker for Parkinson’s DiseaseCurrently available
aSyn seeding​ (RT-QuIC)- Round Robin
CSFHealthy Control
Parkinson Disease
SWEDD (legacy)
NABaseline, 36 months173
45Dong-Gyu Jo, PhDSungkyunkwan University​Study for the Propagation of aSyn (Screening the Propagation Relative Genes)Expected Q2 2023
aSyn propagation
iPSCsHealthy Control
Parkinson Disease
GBA & LRRK2 subjectsn/a174
46Lalitha Madhavan, PhDUniversity of Arizona​Development of a Biomarker Platform for Parkinson’s disease Using Patient-derived CellsExpected Q3 2023
Cellular phenotype biomarkers
Fibroblasts
iPSCs
Healthy Control
Parkinson Disease
NAn/a175
47Kirsten Taylor, PhDRocheaSyn PMCA Assay at AmprionCurrently available
aSyn seeding​ (PMCA in leftover samples)
CSFHealthy Control
Parkinson Disease
NABaseline, 12, 24 months176
48Jennifer Van Eyk, PhDCedars-SinaiPost-Translational Modification & Protein Quantification of Plasma & CSFExpected Q3 2023
Unbiased proteomics (DIA MS, AMP PD)
CSF
Plasma
Healthy Control
Parkinson Disease
NABaseline & 3 longitudinal timepoints177
49Kimberly Billingsley, PhDNIHIdentifying the Role of Structural Variants in PDExpected Q2 2023
Structural variants
DNAHealthy Control
Parkinson Disease
NAVarious179
50Michael Schwarzschild, PhDMGH & DenaliMetabolomic Analysis of Penetrance, Prognosis, & Tracking Biomarkers of LRRK2 PDPlasma available; CSF Expected Q3 2023
Metabolomics
CSF
Plasma
Healthy Control
Parkinson Disease
Prodromal
GBA & LRRK2 subjectsPlasma: Baseline,12, 24 months; CSF: Baseline only180
51Marion Buckwalter, PhDStanfordAdaptive Immune Markers for Predicting Cognitive Decline in PDCurrently available
Immune profiling
CSF
Plasma
Healthy Control
Parkinson Disease
NABaseline, 48 months181
52Shawn Ritchie, PhDMed-Life DiscoveriesValidation of Plasmalogen Augmentation as a Viable Drug Target in PD​Currently available
Plasmalogen​
PlasmaHealthy Control
Parkinson Disease
SWEDD (legacy)
Genetic subjectsBaseline182
53Emmanouil Metzakopian, PhDUniversity of Cambridge ​High-throughput Single Cell Unbiased Lipidomics Assay in Human iPSC-derived​Expected Q3 2023
Lipidomics​
iPSCsHealthy Control
Parkinson Disease
Prodromal
Genetic subjectsn/a183
54Daphne Koller, PhD​InsitroInsitro PPMI Cell Line ApplicationExpected Q2 2023
2D dopaminergic neuronal culture phenotyping​
iPSCsHealthy Control
Parkinson Disease
GBA & LRRK2 subjectsn/a187
55Peter Lewitt, MDHenry Ford Health SystemPolyamine Biomarkers of Parkinson Disease ProgressionExpected Q2 2023
Metabolomics
CSF
Serum
Healthy Control
Parkinson Disease
NABaseline, 24 months189
56Sebastian Virreira Winter, PhDOmicEra​Targeted & Untargeted MS Based Proteomics of Urine in PDCurrently available
Urine proteomics
UrineHealthy Control
Parkinson Disease
Prodromal
GBA & LRRK2 subjectsPD, HC, & GBA: Baseline only; LRRK2: Baseline, 12, 24 months190
57Deniz Kirik, MD, PhDUniversity of Sydney​Circuitry and Brain-body InteractionsExpected Q1 2024
Circuitry*​
iPSCsParkinson Disease
Prodromal
LRRK2 & SNCA subjectsn/a193
58Deniz KirikUniversity of SydneyAn in vivo approach to elucidate the pathobiology of PD-associated genes using human diseased neuronsExpected Q4 2023
Fibroblasts
iPSCs
Healthy Control
Parkinson Disease
NAn/a193
59Alejandro Pezzulo, MDUniversity of IowaMultidisciplinary Analysis of Metabolic Dysregulation in Parkinson's DiseaseExpected Q2 2023
Metabolic profiling
FibroblastsHealthy Control
Parkinson Disease
NAn/a194
60Christos Proukakis, MD, PhDUniversity College LondonDetection of GBA Mutations by Combination of Illumina & Nanopore Sequencing​Currently available
Long read GBA sequencing
DNAParkinson Disease
Prodromal
GBA subjectsVarious195
61Eline Appelmans, PhDFNIHTargeted Proteomics in AMP PDCurrently available
Targeted proteomics (O-Link Explore 1536, AMP PD)​
CSF
Plasma
Healthy Control
Parkinson Disease
NABaseline & 3 longitudinal timepoints196
62Xiqun Chen, MD, PhDMass General Hospital​From Cancer Associations to Altered Immunity in the Pathogenesis of Parkinson’s DiseaseExpected Q2 2024
Inflammation*
iPSCsHealthy Control
Parkinson Disease
LRRK2 subjectsn/a197
63Erika Holzbaur, PhDUPenn​Investigating Mitochondrial Trafficking Deficits Across PD ModelsExpected Q2 2023
Mitochondrial trafficking​
iPSCsHealthy ControlGenetic subjectsn/a198
64Magdalene Moran, PhDCaraway Therapeutics​Developing TMEM175 Activators as Therapeutics for PDExpected Q2 2023
TMEM175 activators​
iPSCsParkinson DiseaseGBA subjectsn/a199
65Adam Mamais, PhDUniversity of Florida​Converging Pathways of LRRK2 & PINK1 Biology Impacting Iron Homeostasis & Mitochondrial FunctionExpected Q2 2023
Iron & mitochondrial homeostasis​
iPSCsHealthy Control
Parkinson Disease
LRRK2 subjectsn/a202
66Massimiliano BianchiUlysses Neuroscience LtdValidation of microtubule dynamics as a novel target in Parkinson’s diseaseExpected Q2 2023
iPSCsHealthy Control
Parkinson Disease
Prodromal
iPD, Hyposmicn/a203
67George Tofaris, MD, PhDUniversity of OxfordSerum Neuronal Exosomes as Predictive or Dynamic Biomarkers in PDExpected Q2 2023
Neuronal exosomes (aSyn)​
SerumParkinson Disease
Prodromal
GBA & LRRK2 subjectsBaseline204
68Kiroaki Kaku, PhDWestern Michigan University​The Role of FAIM in Parkinson’s Disease​Expected Q3 2023
FAIM
iPSCsParkinson DiseaseGBA & SNCA subjectsn/a206
69Karen MacLeod, Claudio Soto, PhDAmprionDevelopment and Optimization of Semi-Quantitate PMCA for Analysis of Soluble ASYN Aggregates in CSF in Amprion's Clinical LaboratoryCurrently available
aSyn seeding (PMCA)
CSFHealthy Control
Parkinson Disease
NAVarious207Used warmed CSF from various visits
70ZinnhardtRocheIdentification of NLRP3 Inflammasome-related biomarkers in PPMI CSF SamplesCurrently available
CSF209
71Anumantha Kanthasamy, PhDIowa State UniversityPPMI a-Syn Skin Seeding AssayExpected Q3 2023
aSyn seeding​ (RT-QuIC)- Round Robin
SkinHealthy Control
Parkinson Disease
NABaseline211
72Khalil RamadiNew York UniversityNeural Chemical Delivery System for Treatment of Parkinson's DiseaseExpected Q3 2024
Fibroblasts
iPSCs
Healthy Control
Parkinson Disease
NAn/a216
73Rebecca Selzer, PhDFUJIFILM Cellular Dynamics, Inc.Production and Commercialization of Differentiated Cell TypesExpected Q3 2023
Dopaminergic neurons
iPSCsHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsn/a218Differentiation into commercially available dopaminergic neurons
74Julian Peter SefrinAbbvieEvaluation of TMPRSS5 (Spinesin) in the CSF as a potential biomarker for early Parkinson’s disease diagnosis and progressionCurrently available
CSFParkinson Disease
Prodromal
Phenoconverters, Short Duration iPD, Genetic Subjects, Hyposmic, RBDBL, 6, 12, 24, 36, 48, 60 Months219
75Omar MabroukBiogenCSF total LRRK2 measurements as a Biomarker in genetic PDCurrently available
CSFHealthy Control
Parkinson Disease
Prodromal
GBA & LRRK2 subjectsBL, 24 Months221
76Anthony SchapiraUCL Medical SchoolThe genome-microbiome axis in the cause of Parkinson disease: Mechanistic insights and therapeutic implications from experimental models and a genetically stratified patient population.Expected Q1 2024
iPSCsHealthy Control
Parkinson Disease
NAn/a223
77Céline GalvagnionUniversity of CopenhagenUnderstanding selective neuronal vulnerability in the context of Parkinson's DiseaseExpected Q1 2024
iPSCsHealthy Control
Parkinson Disease
LRRK2, iPDn/a224
78Susanna NarkilahtiUniversity of TampereElectrophysiological Phenotype Characterization of iPSC-derived Neuronal Cells with PD-linked LRRK2 Mutations during Network Formation and Alpha-Synuclein Seeded AggregationExpected Q2 2024
iPSCsHealthy Control
Parkinson Disease
Prodromal
LRRK2 G2019S, LRRK2 R1441Gn/a227
79Sonia GandhiUniversity College LondonDefining mechanisms in neurons and oligodendrocytes that drive progression in Parkinson’sExpected Q4 2024
iPSCsHealthy Control
Parkinson Disease
Prodromal
iPD, SNCA (A53T), Hyposmic, RBDn/a229
80Rhalena ThomasMcGill UniversityA pipeline for massive multiplexing of iPSC-derived dopaminergic neurons and microglia for cohort-scale transcriptomics in PDExpected Q4 2024
iPSCsHealthy Control
Parkinson Disease
Prodromal
iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), Hyposmicn/a230
81Lezanne OoiUniversity of WollongongMetabolic phenotyping in PD dopaminergic neurons and neuronal-glial co-cultures using high-throughput single-cell metabolomics and lipidomicsExpected Q2 2024
iPSCsHealthy Control
Parkinson Disease
Prodromal
iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), Hyposmicn/a231
82Gist CroftThe New York Stem Cell FoundationA cohort-wide resource of transcriptomic and morphological phenotypes in defined neural cell typesExpected Q2 2024
iPSCsHealthy Control
Parkinson Disease
Prodromal
iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), Hyposmic, RBDn/a232
83Yuriy PomeshchikLund UniversityUncovering proteomic alterations in Parkinson’s disease using patient-specific iPSC-derived brain cellsExpected Q2 2024
iPSCsHealthy Control
Parkinson Disease
Prodromal
iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), Hyposmicn/a233
84Laurent RoybonVARIOmic-based analyses of PD iPSC-derived brain cellsExpected Q3 2024
iPSCsHealthy Control
Parkinson Disease
Prodromal
iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), Hyposmicn/a234
85Lalitha MadhavanUniversity of ArizonaDeep phenotyping of PD relevant mitochondrial and autophagic mechanisms in human iPSC-derived neural cellsExpected Q4 2024
iPSCsHealthy Control
Parkinson Disease
iPD, HCn/a235
86Souvik ModiESYA LabsESYA PD360: A multi-parametric platform for establishing a novel lysosome-based biomarker and identifying therapeutic interventions for Parkinson’s DiseaseExpected Q1 2024
FibroblastsHealthy Control
Parkinson Disease
iPDn/a236
87Daniel YsselsteinVanqua BioGlucocerebrosidase Activation as a Therapeutic Strategy for Parkinson’s DiseaseExpected Q1 2024
iPSCsHealthy Control
Parkinson Disease
GBA, iPDn/a239
88Hilde NilsenOslo University HospitalMitochondrial Transcription regulation via Base Excision RepairExpected Q1 2024
iPSCsHealthy Control
Parkinson Disease
Prodromal
SNCAn/a241
89Peggy Taylor, PhDBioLegendaSyn Measurements in Longitudinal CSF Samples From De Novo, PD, CT, SWEDD, Prodromal, & Genetic Cohorts​Currently available
total aSyn, hemoglobin, & total protein
CSFHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaseline, 6, 12, 24, 36 months124PD, HC, SWEDD through yr 3, prodromal & genetic through yr 1
90Andrew Singleton, PhDNIASelected Genetic Variants Genotyped Using NeuroX ArrayCurrently available
NeuroX genotyping
DNA from whole bloodHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaseline106/107
91Les Shaw, PhDUPennA-beta 1-42, t-tau and p-tau 181 Measurements in PPMI CSF Samples using xMAP/Luminex Multiplex Immunoassay & Roche ElecsysCurrently available
Aβ, tau, & p-tau181 ​
CSFHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaseline, 6, 12, 24, 36 months110, 125Innogentics: PD, HC, & SWEDD through yr 1; Elecsys: PD, HC, & SWEDD through yr 3, prodromal & genetic through yr 1
92Kendall Van Keuren-Jensen, PhDTGen FoundationRNAseq in PPMICurrently available (summary files, raw data for cloud transfer, & data explorer)​
mRNA& miRNA sequencing​
RNA from whole bloodHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaselilne, 6, 12, 24, 36 months131, 133Data available as summary files, raw data for cloud transfer, & data explorer
93Pablo Sardi, PhDSanofiGBA-Related Biomarkers in Parkinson's DiseaseCurrently available
GCase activity & sphingolipids​
CSF
Plasma
Whole blood
Healthy Control
Parkinson Disease
SWEDD (legacy)
NABaseline, 12, 24, 36 months132, 135
94Bahareh Ajami, Dario AlessiOregon Health & Science University, University of DundeeInvestigating the influence of genetic risk factors of PD on peripheral immune cells to identify potential biomarkers for prediction of conversion of non-manifesting to manifesting carriers.Expected Q3 2023
PBMCs
Plasma
Parkinson DiseaseNAn/a213
95Luis ConchaAmprionAnalysis of CSF samplesExpected Q4 2023
CSFHealthy Control
Parkinson Disease
Prodromal
NABL, 6, 12 Months237
96Nick HertzMitokininAssessing pS65 Ubiquitin levels in biofluids as a biomarker for Parkinson's DiseaseExpected Q4 2023
CSF
Plasma
Healthy Control
Parkinson Disease
Prodromal
NABL, 6, 12, 24, 36, 48, 60 Months240